hASCs were able to modulate Th17 responses by inhibiting the gene expression and/or secretion of IL-17, IL-21, and/or IL-6 by PHA-activated PBMCs isolated from RA vs. healthy donors, with more intense suppressive effects in the RA group due to their priming by the patients’ inflammation. The gene discussed is IL6; the disease is rheumatoid arthritis.